Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-3.35%
$1.71
0% positive prob.
5-Day Prediction
-10.27%
$1.59
0% positive prob.
20-Day Prediction
-63.32%
$0.65
0% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q2 2026 | SELL | -3.35% | -10.27% | -63.32% | 100.0% | -8.47% |
| Q3 2025 | BUY | +20.85% | +3.86% | +21.24% | 100.0% | +9.15% |
SEC 8-K filings with transcript text
Aug 11, 2026 · 100% conf.
1D
-3.35%
$1.71
Act: -14.69%
5D
-10.27%
$1.59
Act: -8.47%
20D
-63.32%
$0.65
2 ex99-1.htm
Exhibit 99.1
Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives
LAKE CITY, Utah – August 11, 2026 – SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today provided a business update in conjunction with the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.
During the first half of 2026, SINTX advanced the commercialization of its FDA-cleared SiNAPTIC® Foot & Ankle Implant System, expanded its commercial distribution network, raised additional capital, invested in advanced manufacturing capabilities, and continued to broaden the application of its proprietary silicon nitride technology platform across multiple healthcare and industrial markets.
These accomplishments reflect the Company’s strategic transition from technology development toward commercial execution while continuing to build a diversified portfolio of growth opportunities designed to create long-term shareholder value.
“Our strategy has always extended well beyond the introduction of a single medical device,” said Eric K. Olson, Chairman, President and Chief Executive Officer of SINTX Technologies. “During the first half of 2026, we continued building the commercial infrastructure, manufacturing capabilities, and strategic relationships necessary to support our growth strategy, while raising additional capital and implementing measures designed to preserve liquidity and improve operating efficiency. We believe silicon nitride represents a differentiated technology platform with the potential to address multiple high-value healthcare and industrial markets, and we remain focused on translating these investments into increasing commercial adoption, expanding revenue opportunities and potential long-term value creation.”
Commercial Execution Accelerates
Following FDA 510(k) clearance in October 2025, SINTX initiated a Limited Use Release (“LUR”) of its SiNAPTIC® Foot & Ankle Osteotomy Wedge System during the first half of 2026. The LUR is intended to support surgeon training, clinical adoption and commercialization ahead of broader market expansion.
To support this commercialization effort, the Company established its initial network of twelve independent orthopedic distributors specializing in foot and ankle surgery. As surgeon adoption continues to expand, SINTX expects this commercial infrastructure to support broader market penetration throughout the United States.
The Company believes SiNAPTIC’s proprietary silicon nitride biomaterial offers meaningful clinical differentiation through its demonstrated bone affinity and inherent resistance to bacterial adhesion, characteristics that position the platform for potential expansion into additional orthopedic applications.
Multiple Revenue Opportunities Continue to Expand
While advancing commercialization of its medical technologies, SINTX continued to expand its established industrial ceramics business.
During the first half of 2026, the Company received approximately $3.2 million in new industrial purchase orders from multiple contract manufacturing customers for the production of advanced ceramic components serving demanding, high-performance applications. Initial shipments have commenced, and the Company currently expects to recognize revenue associated with these purchase orders beginning in the third quarter of 2026, subject to delivery schedules, customer acceptance and applicable revenue-recognition requirements.
Management believes the industrial business provides an important commercial foundation that supports continued investment in higher-growth medical technologies while diversifying the Company’s revenue base.
Revenue Outlook for the Second Half of 2026
Reflecting increased commercial activity and the commencement of production and shipments associated with previously announced customer purchase orders, SINTX currently expects total revenue to be approximately $900,000 to $1.1 million for the third quarter of 2026 and approximately $1.0 million to $1.3 million for the fourth quarter of 2026.
This outlook is based on current production schedules, customer requirements and management’s expectations regarding manufacturing execution, shipments and the timing of revenue recognition. The Company’s outlook is subject to significant uncertainty, including potential changes in customer schedules, material availability, manufacturing yield and capacity, quality release, shipment timing, customer acceptance and product mix. Accordingly, actual results could differ materially from these expectations.
The Company continues to view the approximately $3.2 million of previously announced industrial purchase orders as an important source of commercial visibility, while recognizing that purchase
Nov 13, 2025 · 100% conf.
1D
+20.85%
$3.70
Act: +2.94%
5D
+3.86%
$3.18
Act: +9.15%
20D
+21.24%
$3.71
Act: +20.59%
false 0001269026
0001269026
2025-11-13 2025-11-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
8-K
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 13, 2025
Technologies, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-33624
84-1375299
(State or other jurisdiction
of incorporation)
(Commission
File Number)
Employer
Identification No.)
1885 West 2100 South
Salt Lake City, UT
84119
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (801) 839-3500
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:
Trading Symbol(s):
Name of each exchange on which registered:
Common Stock, par value $0.01 per share
The NASDAQ Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 13, 2025, SINTX Technologies, Inc. (the “Company”) issued a press release announcing financial results for its quarter ended September 30, 2025. The full text of the press release, which includes information regarding the Company’s use of a non-GAAP financial measure, is furnished as Exhibit 99.1 to this Form 8-K.
The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. Furthermore, the information contained in this Item 2.02 or Exhibit 99.1 shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Item 7.01. Regulation FD. Disclosure.
The information set forth under Item 2.02 is incorporated by reference as if fully set forth herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press Release, dated November 13, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 13, 2025 /s/ Eric Olson
Eric Olson
President and Chief Executive Officer
May 15, 2025
false 0001269026
0001269026
2025-05-15 2025-05-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington,
8-K
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 15, 2025
Technologies, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-33624
84-1375299
(State or other jurisdiction
of incorporation)
(Commission
File Number)
Employer
Identification No.)
1885 West 2100 South
Salt Lake City, UT 84119
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (801) 839-3500
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:
Trading Symbol(s):
Name of each exchange on which registered:
Common Stock, par value $0.01 per share
The NASDAQ Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On May 15, 2025, SINTX Technologies, Inc. (the “Company”) issued a press release announcing financial results for its quarter ended March 31, 2025 as well as a business update. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K.
The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. Furthermore, the information contained in this Item 2.02 or Exhibit 99.1 shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Item 7.01. Regulation FD. Disclosure.
The information set forth under Item 2.02 is incorporated by reference as if fully set forth herein.
Item 9.01 Financial Statements and Exhibits.
Exhibit No.
Description
99.1
Press Release, dated May 15, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Technologies, Inc.
Date: May 15, 2025
By: /s/ Eric K. Olson
Eric K. Olson
Chief Executive Officer
This page provides SiNtx Technologies Inc. (SINT) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on SINT's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.